Q1 2018 Earnings Estimate for Spero Therapeutics Inc (SPRO) Issued By Oppenheimer

Spero Therapeutics Inc (NASDAQ:SPRO) – Stock analysts at Oppenheimer boosted their Q1 2018 earnings per share (EPS) estimates for shares of Spero Therapeutics in a report released on Tuesday, April 3rd. Oppenheimer analyst J. Olson now expects that the company will post earnings per share of ($1.67) for the quarter, up from their prior forecast of ($2.34). Oppenheimer currently has a “Buy” rating and a $30.00 target price on the stock. Oppenheimer also issued estimates for Spero Therapeutics’ Q2 2018 earnings at ($1.31) EPS, Q3 2018 earnings at ($1.58) EPS, Q4 2018 earnings at ($1.11) EPS, FY2018 earnings at ($5.43) EPS, FY2019 earnings at ($5.83) EPS, FY2020 earnings at ($6.54) EPS and FY2021 earnings at ($4.59) EPS.

How to Become a New Pot Stock Millionaire

A number of other analysts have also recently commented on the company. Cantor Fitzgerald restated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a research report on Monday, April 2nd. Zacks Investment Research upgraded Spero Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, ValuEngine upgraded Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Spero Therapeutics has a consensus rating of “Hold” and a consensus price target of $24.25.

Shares of SPRO opened at $13.86 on Friday. The stock has a market capitalization of $205.48 and a price-to-earnings ratio of -0.78. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Monday, April 2nd. The company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.77) by $0.18. The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $0.40 million.

Several large investors have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $103,000. California State Teachers Retirement System purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $112,000. Dean Capital Investments Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $118,000. Deutsche Bank AG purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $155,000. Finally, California Public Employees Retirement System purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $294,000. Hedge funds and other institutional investors own 46.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Q1 2018 Earnings Estimate for Spero Therapeutics Inc (SPRO) Issued By Oppenheimer” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3336743/q1-2018-earnings-estimate-for-spero-therapeutics-inc-spro-issued-by-oppenheimer.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate Container Store Group Inc  Will Post Quarterly Sales of $231.21 Million
Zacks: Analysts Anticipate Container Store Group Inc Will Post Quarterly Sales of $231.21 Million
Emphy  Price Reaches $0.15 on Top Exchanges
Emphy Price Reaches $0.15 on Top Exchanges
CanYaCoin Trading 21.5% Higher  This Week
CanYaCoin Trading 21.5% Higher This Week
$214.56 Million in Sales Expected for Wheaton Precious Metals Co.  This Quarter
$214.56 Million in Sales Expected for Wheaton Precious Metals Co. This Quarter
Brokerages Anticipate Del Frisco’s Restaurant Group  Will Post Quarterly Sales of $85.62 Million
Brokerages Anticipate Del Frisco’s Restaurant Group Will Post Quarterly Sales of $85.62 Million
White Gold Corp.  Director David D’onofrio Acquires 49,000 Shares
White Gold Corp. Director David D’onofrio Acquires 49,000 Shares


© 2006-2018 Ticker Report. Google+.